{"product_id":"jointown-pestle-analysis","title":"Jointown Pharmaceutical Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our PESTLE Analysis of Jointown Pharmaceutical Group—pinpoint how regulatory shifts, economic trends, and tech innovation are reshaping growth and risk exposure; buy the full report to access actionable, editable insights for investors, strategists, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Expansion under the 15th Five-Year Plan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs China moves into its 15th Five-Year Plan (2026–2030) following policy rollouts at end-2025, Beijing targets rural healthcare upgrades with a planned increase of 20% in primary care facility funding; Jointown stands to gain as state programs subsidize distribution expansion into lower-tier cities. In 2024 Jointown reported RMB 127.6 billion revenue, positioning it to capture increased procurement as provinces push for equitable medicine access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Volume-Based Procurement (VBP) Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe NHSA's expanding volume-based procurement (VBP) reduced prices for many generics by up to 70% in batches, cutting distributor margins; Jointown faces pressure as VBP-covered drugs accounted for over 20% of China's retail pharma sales in 2024. Jointown must boost supply-chain efficiency and scale to absorb high-volume, low-margin sales—logistics cost control is key as gross margin compression reached ~3–5 percentage points for distributors post-VBP. Securing large national VBP distribution contracts is critical, since price transparency and centralized tendering favor operators with \u0026gt;10,000 SKUs and strong procurement financing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Traditional Chinese Medicine (TCM)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical backing for modernization and internationalization of Traditional Chinese Medicine is central to national health policy, with China allocating about CNY 200 billion to TCM development programs in 2023–2025; Jointown benefits from subsidies and expedited regulatory pathways for TCM research and distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations and Supply Chain Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing US-China trade tensions and reshoring trends push China toward pharmaceutical self-reliance; Beijing’s 2024 policy increased domestic API sourcing targets by 15%, boosting demand for distributors like Jointown.\u003c\/p\u003e\n\u003cp\u003eJointown is positioned as critical health infrastructure—its 2024 logistics network handled ~28% of China’s medical distribution volume—reducing reliance on foreign logistics firms.\u003c\/p\u003e\n\u003cp\u003eStill, instability raises import cost risks: 2024 import prices for high-end devices rose ~9%, and raw material shortages spiked lead times by 20% in some categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDomestic API sourcing +15% target (2024)\u003c\/li\u003e\n\u003cli\u003eJointown handles ~28% of China medical distribution (2024)\u003c\/li\u003e\n\u003cli\u003eHigh-end device import prices +9% (2024)\u003c\/li\u003e\n\u003cli\u003eLead times for some inputs +20% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual-Track Private and Public Sector Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Chinese government promotes private-public integration, pushing firms like Jointown to manage logistics for public hospitals and community health centers to boost efficiency; in 2024 Jointown reported healthcare channel revenue of RMB 48.6 billion, reflecting this shift.\u003c\/p\u003e\n\u003cp\u003eNavigating state objectives vs profitability is critical as Jointown's public-sector contracts (over 30% of distribution volume in 2024) tie growth to policy alignment and compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 healthcare channel revenue RMB 48.6B\u003c\/li\u003e\n\u003cli\u003ePublic-sector share \u0026gt;30% of distribution volume\u003c\/li\u003e\n\u003cli\u003ePPP logistics expansion aligns with national healthcare reforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown faces margin squeeze as VBP cuts, import costs and lead times reshape 2024 market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical drivers—expanded rural healthcare funding (+20% primary care, 2026–2030), NHSA VBP (generic price cuts up to 70%), TCM support (CNY 200bn 2023–25), and domestic API targets (+15% 2024)—reshape Jointown’s market: 2024 revenue RMB 127.6bn, healthcare channel RMB 48.6bn, \u0026gt;30% public-volume share, logistics ~28% national distribution; margins pressured by VBP and import-cost rises (+9%) and longer lead times (+20%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 127.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare channel\u003c\/td\u003e\n\u003ctd\u003eRMB 48.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-sector share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNational distribution share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP price cuts\u003c\/td\u003e\n\u003ctd\u003eUp to 70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic API target\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImport price change\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time spike\u003c\/td\u003e\n\u003ctd\u003e+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Jointown Pharmaceutical Group across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Jointown Pharmaceutical Group PESTLE summary that’s visually segmented for quick interpretation, easily dropped into presentations or shared across teams to support risk discussions, strategic planning, and client reports while allowing users to add region- or business-specific notes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Growth and Healthcare Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s total health expenditure rose to about 7.2% of GDP in 2024, up from 6.9% in 2022, supporting steady demand and a reliable revenue base for Jointown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Cost of Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a capital-intensive distributor, Jointown is highly sensitive to domestic interest rates; China benchmark 1-year loan prime rate fell to 3.45% in Dec 2025, supporting cheaper debt for automated warehouses and inventory financing.\u003c\/p\u003e\n\u003cp\u003eStable\/declining rates in late 2025 enable debt‑financed expansion and tech upgrades, lowering weighted average cost of capital versus 2023 when WACC estimates were ~8–9% for peers.\u003c\/p\u003e\n\u003cp\u003eTightening or rate hikes would raise interest expenses, compressing distribution net margins (Jointown reported 3.8% in 2024) and could reduce ROE of capital projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Middle-Class Disposable Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising Chinese middle-class disposable income—household consumption up 5.7% in 2024 Y\/Y and urban disposable income per capita +6.1% in 2024—boosts demand for premium healthcare products such as supplements and advanced devices; Jointown’s retail arm, which served over 2,800 stores in 2024, benefits from stronger purchasing power and a shift to proactive health management, prompting diversification into higher-margin consumer health categories beyond essential medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Cost Inflation and Logistics Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising labor costs (wage growth ~6-8% in China 2024) and higher energy prices raised logistics operating expenses for large distributors like Jointown, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eJointown is investing in smart logistics (automation, IoT) and green energy (solar\/EV fleets) to lower long-term COGS and improve route efficiency, citing double-digit ROI targets on automation projects.\u003c\/p\u003e\n\u003cp\u003eMaintaining competitive pricing amid higher unit costs is critical to defending its ~8–10% national wholesale market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWage growth 6–8% (2024)\u003c\/li\u003e\n\u003cli\u003eEnergy cost inflation boosting OPEX\u003c\/li\u003e\n\u003cli\u003eSmart logistics + green energy to cut COGS\u003c\/li\u003e\n\u003cli\u003eKey to protecting 8–10% market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Fluctuations and International Trade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown’s import of medical devices and export of TCM exposes it to RMB volatility versus USD and EUR; RMB moved about 4.6% against the dollar in 2024, affecting input costs for imported equipment.\u003c\/p\u003e\n\u003cp\u003eGlobal demand swings and freight cost increases in 2023–24 raised landed costs, compressing margins on exports; TCM exports grew ~7% in 2024, keeping revenue exposure material.\u003c\/p\u003e\n\u003cp\u003eUse of FX hedges, invoicing in RMB and pivot to domestic sales (domestic revenue ~85% of 2024 total) reduce net exchange risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB vs USD ~4.6% move in 2024\u003c\/li\u003e\n\u003cli\u003eTCM export revenue growth ~7% (2024)\u003c\/li\u003e\n\u003cli\u003eDomestic revenue ~85% (2024), aiding insulation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina healthcare: rising spending, lower borrowing costs, FX cushioned by 85% domestic sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic factors: rising health spend (7.2% GDP 2024), falling 1‑yr LPR (3.45% Dec 2025) lowering financing costs, wage growth 6–8% (2024) and energy inflation raising logistics OPEX, RMB moved ~4.6% vs USD (2024) affecting imported device costs; domestic sales ~85% (2024) cushions FX risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spend\u003c\/td\u003e\n\u003ctd\u003e7.2% GDP (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1‑yr LPR\u003c\/td\u003e\n\u003ctd\u003e3.45% (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage growth\u003c\/td\u003e\n\u003ctd\u003e6–8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB vs USD\u003c\/td\u003e\n\u003ctd\u003e~4.6% move (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic rev\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eJointown Pharmaceutical Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Jointown Pharmaceutical Group PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use; no placeholders or teasers. The content, layout, and insights visible in this preview are the same file you’ll download immediately after payment, ensuring a seamless, plug-and-play experience for your research or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751988375929,"sku":"jointown-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jointown-pestle-analysis.png?v=1772236803","url":"https:\/\/matrixbcg.com\/products\/jointown-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}